A clinical trial of enflurane with paediatric patients is reported and confirms that it is a satisfactory inhalational anaesthetic agent without serious adverse effects.
References
1.
BrownT. C. K. (1975): (unpublished data).
2.
ColeW. H. J. (1961): “A Simple Halothane Vapourizer”, Brit. J. Anaesth., 33, 319.
3.
DobkinA. B., HeinrichR. G., IsraelJ. S., LevyA. A., NevilleJ. F., OunkasomK. (1968): “Clinical and Laboratory Evaluation of a New Inhalational Agent: Compound 347. (CHF2–O–CF2–CH FCL), Anesthesiology, 29, 275.
4.
GreeneW. (1963): Inhalation Anaesthetics and Carbohydrate Metabolism, Williams and Wilkins.
5.
KrantzJ. C., CarrC. J.Jr., LuG., BellF. K. (1953): “Anaesthesia XL: The Anaesthetic Action of Trifluoro-ethyl-vinyl Ether”, J. Pharmacol. Exp. Ther., 108, 488.
6.
LebowitzM. H., BlittC. D., DillonJ. B. (1970): “Clinical Investigation of Compound 347 (Ethrane), Anesth. Analg. Curr. Res., 49, 1.
7.
MazzeR. I., CousinsM. J. (1973): “Renal Toxicity of Anaesthetics with Special Reference to Nephrotoxicity of Methoxyflurane”, Canad. Anaesth. Soc. J., 20, 68.
8.
SimpsonB. R., StruninL., WaltonB. (1973): “Halothane Hepatitis—Fact or Fallacy?Proc. Roy. Soc. Med., 66, 56.
